TerminatedPhase 2NCT00042952

Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer

Studying Germ cell tumor of testis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Christopher Ryan
Cancer and Leukemia Group B
Intervention
imatinib mesylate(drug)
Enrollment
32 enrolled
Eligibility
15 years · All sexes
Timeline
2002

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00042952 on ClinicalTrials.gov

Other trials for Germ cell tumor of testis

Additional recruiting or active studies for the same condition.

See all trials for Germ cell tumor of testis

← Back to all trials